Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2007

EvoGenix Optimizes GSK Protein Product

  • EvoGenix successfully completed the first project in a collaboration with GlaxoSmithKline. EvoGenix thus received a milestone payment.

    EvoGenix utilized its protein optimization technology, EvoGene™, to develop improved versions of a protein product from the GSK pharmaceutical pipeline. The protein variants generated had improvements in affinity that exceeded the 20-fold goal specified in the agreement.

    GSK will be responsible for further development of the product, with EvoGenix eligible to receive additional milestone payments as the product progresses through the pipeline. EvoGenix is also set to earn royalties on product sales should it be approved and launched.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »